Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cognition Therapeutics Inc
CGTX
Healthcare
Biotechnology
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular...
degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CGTX)
New Post
View:
Posts & Comments
Threaded Posts
(282)
•••
whytestocks
X
Post by
whytestocks
on Nov 26, 2024 7:45pm
Cognition Therapeutics Announces all Participants have Compl
BREAKING NEWS: $CGTX Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies@ Topline results
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Nov 12, 2024 12:32pm
Life Sciences Investor Forum Agenda Announced for November 1
Breaking News: $CGTX Life Sciences Investor Forum Agenda Announced for November 14thNEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor
...more
Promino Nutritional Sciences Inc. Provides Shareholder Progress Report
posted Dec 14, 2024 9:00am by
Promino Nutritional Sciences Inc.
-
|
Promino Nutritional Science's rejuvenate muscle activator, delivers the equivalent of 40 grams of whey protein isolate for just 3.6 grams of the company’s product. That was just one of the highlights in the company’s update to investors covering a transformational period for the company as new management resurrects sales with an eye on the RTD market in 2025 ...read more
(282)
•••
whytestocks
X
Post by
whytestocks
on Aug 22, 2024 11:47am
Cognition Therapeutics Publishes EEG Findings from Phase 2 S
Breaking News: $CGTX Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseasePURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Jul 26, 2024 4:19pm
Cognition Therapeutics to Host Investor Webcast to Discuss R
Just In: $CGTX Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET
...more
(27)
•••
ubiquitousman
X
Post by
ubiquitousman
on May 20, 2023 1:40pm
Ok, I will start, stock closed at $2.17 5-19-23-could be ..
interesting. Different take on AD. High risk play but I could make a case for this to be a $50-$100 stock in 24 months if they can prove efficacy in AD treatment. Stay tuned. Minute market cap of
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.